Search for: "DNA Diagnostics, Inc."
Results 1 - 20
of 157
Sorted by Relevance
|
Sort by Date
3 Aug 2020, 9:59 pm
Ariosa Diagnostics, Inc. [read post]
8 Aug 2016, 8:46 am
Personal Genome Diagnostics Inc., a Baltimore-based provider of advanced cancer genome testing products and services, today announced an agreement with Illumina, Inc. to develop two in-vitro diagnostic test kits for use on Illumina’s sequencing instruments, including kits for the detection and characterization of tumor DNA using both tissue and plasma samples. [read post]
24 Mar 2020, 2:08 am
In Illumina, Inc. v. [read post]
1 Nov 2021, 1:45 am
In Australia, the Federal Court recently confirmed that the test for the patent eligibility of a diagnostic method is whether the method has economic utility (Ariosa Diagnostics, Inc v Sequenom, Inc [2021] FCAFC 101). [read post]
25 May 2020, 11:15 am
Ariosa Diagnostics, Inc., No. 2019-1419 (Fed. [read post]
25 May 2020, 11:15 am
Ariosa Diagnostics, Inc., No. 2019-1419 (Fed. [read post]
17 Mar 2020, 2:25 pm
The patents at issue in the case acknowledge but are not related to the patented invention held invalid in Ariosa Diagnostics, Inc. v. [read post]
27 Dec 2018, 8:42 pm
District Court Judge Susan Illston stuck again on Christmas Eve, giving the biotech patent community a rhetorical lump of coal in their stocking by invalidating on summary judgment claims directed to methods for isolating cell-free fetal DNA from maternal DNA on the grounds that they are not patent-eligible under 35 U.S.C. [read post]
2 May 2023, 9:08 am
Eurofins Viracor, Inc. [read post]
19 Jan 2017, 7:13 am
Myriad Genetics, Inc., 133 S.Ct. 2107 (2013)] significantly changed the legal landscape of DNA patentability. [read post]
17 Mar 2020, 2:25 pm
The patents at issue in the case acknowledge but are not related to the patented invention held invalid in Ariosa Diagnostics, Inc. v. [read post]
10 Jun 2012, 9:40 pm
Prometheus, Inc., decision, (see our March 20th post) and is currently under review by the U.S. [read post]
7 Feb 2014, 2:37 pm
Noonan -- Gene-by-Gene, Inc. was one of the first direct-to-consumer (DTC) genetic diagnostics companies to announce that it would offer BRCA1/BRCA2 testing after the Supreme Court's decision last June that certain of Myriad Genetics' claims (those that encompassed isolated genomic DNA) were invalid for reciting patent-ineligible subject matter. [read post]
1 Nov 2013, 7:08 am
Ariosa Diagnostics, Inc. v. [read post]
23 Dec 2019, 9:21 pm
Ariosa Diagnostics, Inc. by invalidating on summary judgment claims directed to methods for isolating cell-free fetal DNA from maternal DNA on the grounds that they are not patent-eligible under 35 U.S.C. [read post]
8 Nov 2013, 11:33 am
Ariosa Diagnostics, Inc. v. [read post]
17 Mar 2020, 1:02 pm
Ariosa Diagnostics, Inc. [read post]
31 Mar 2020, 9:58 am
Cir. 2019); Athena Diagnostics, Inc. v. [read post]
16 Nov 2009, 5:29 pm
" While the company has developed and markets six such DNA-based diagnostic tests, it has primarily been devoted to research and development. [read post]
15 Jul 2012, 8:55 pm
DNA Diagnostics Center, Inc. 0:12-cv-01668; filed July 11, 2012 in the District Court of Minnesota Canine EIC Genetics, LLC v. [read post]
